Cognitive Impairment Associated with Schizophrenia: A Case Report
Introduction: First-generation antipsychotics could reduce the positive symptoms of schizophrenia but also impair cognitive function. Cognitive and negative symptoms in schizophrenia could be a significant burden experienced both by the patients and caregivers. Thus the treatment of cognitive impairment associated with schizophrenia should be addressed properly. The purpose of writing this article is to increase awareness in administering antipsychotics to elderly patients with schizophrenia, especially in the cognitive aspect and how to overcome possible cognitive decline. Case: An outpatient female schizophrenic patient who was on first-generation antipsychotic treatment complained of forgetfulness. The complaint started 5 years after she received her treatment. While she could still perform her activities of daily living independently, her instrumental activities of daily living were impaired. Her food got burnt while she was cooking, and she also took her medicine excessively because she forgot about it. Both of those events could be very dangerous for her. Discussion: Antipsychotics are the first-line pharmacotherapy for the treatment of schizophrenia but could also cause cognitive impairment. Management of cognitive impairment associated with schizophrenia could be performed both non-pharmacologically, by giving cognitive remediation therapy or physical exercise, and pharmacologically, by giving cholinergic agents such as donepezil. Conclusions: Cognitive impairment associated with schizophrenia should be managed as well as psychotic symptoms.
Copyright (c) 2025 Lia Jessica, Yulia Fatima Bessing, Erikavitri Yulianti

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. Copyright of this journal is possession of the Author, by the knowledge of the Editorial Board and Journal Manager, while the moral right of the publication belongs to the author.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The articles are published under a Creative Commons Attribution Share-Alike (CC BY-SA) license. Many research funding bodies prefer the CC BY-SA license because it allows for maximum dissemination and re-use of open access materials. Users are free to share (copy, distribute, and transmit) and remix (adapt) the contribution under this license, including for commercial purposes, as long as they attribute the contribution in the manner specified by the author or licensor.